



Patent Application
Attorney Docket No. PC25489A

TFW

hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents P. O. Box 1450, Alexandria, VA 22313-1450 on this 13th day of September 2004

By _____

Irene Grantham

(Signature of person mailing)

Irene Grantham

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Gillian Munro Burgess, et al.

APPLICATION NO.: 10/799,191 : Examiner: To Be Assigned

FILING DATE: 03/12/2004 : Group Art Unit: 1614

TITLE: TREATMENT OF TYPE 1 DIABETES WITH PDE5 INHIBITORS

Hon. Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820, which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Patent Application
Attorney Docket No. PC25489A

A prompt and favorable response is earnestly solicited.

Date: Sept. 13, 2004
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-4288

Respectfully submitted,

Martha G. Munchhof
Martha G. Munchhof
Attorney for Applicant(s)
Reg. No. 47,811



SEP 15 2004

| | | | | | | | | | | | | | |
|--|--|-----------------|---|-----------------|--|--|--|---|---------------|-----------------------|-----------------|----------------------------|----|
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | | | | | | | | ATTY. DOCKET NO. PC25489A | | SERIAL NO. 10/799,191 | | | |
| | | | | | | | | APPLICANT Gillian Munro Burgess, et al. | | | | | |
| | | | | | | | | FILING DATE March 12, 2004 | | GROUP 1614 | | | |
| U.S. PATENT DOCUMENTS | | | | | | | | | | | | | |
| EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| FOREIGN PATENT DOCUMENTS | | | | | | | | | | | | | |
| DOCUMENT NUMBER JP H08- 2 0 8 4 7 5 | | | | | | | | DATE 8/13/96 | COUNTRY Japan | CLASS A61K | SUBCLASS 31/445 | TRANSLATION | |
| | | | | | | | | | | | | YES | NO |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| | | | "Review of HGM-CoA Reductase Inhibitors", Pharmazie in unserer Zeit 28(3), pp. 147-152 (1999) – English Translation | | | | | | | | | | |
| | | | | | | | | | | | | | |
| | | | | | | | | | | | | | |
| EXAMINER | | | | DATE CONSIDERED | | | | | | | | | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | | | | | | | |